These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

907 related articles for article (PubMed ID: 31841714)

  • 21. Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.
    Zeng L; Xiao L; Jiang W; Yang H; Hu D; Xia C; Li Y; Zhou C; Xiong Y; Liu L; Liao D; Guan R; Li K; Wang J; Zhang Y; Yang N; Mansfield AS
    Lung Cancer; 2020 Mar; 141():82-88. PubMed ID: 31982639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
    Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
    Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.
    Wang Z; Chen R; Wang S; Zhong J; Wu M; Zhao J; Duan J; Zhuo M; An T; Wang Y; Bai H; Wang J
    PLoS One; 2014; 9(11):e110780. PubMed ID: 25405807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: A real-world multicentric cohort analysis from India.
    Garg A; Batra U; Choudhary P; Jain D; Khurana S; Malik PS; Muthu V; Prasad KT; Singh N; Suri T; Mohan A
    Curr Probl Cancer; 2020 Jun; 44(3):100570. PubMed ID: 32498966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study.
    Bergqvist M; Christensen HN; Wiklund F; Bergström S
    Int J Cancer; 2020 May; 146(9):2510-2517. PubMed ID: 31350754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
    Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
    Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
    Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
    Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non-small-cell Lung Cancer.
    Zhu YJ; Qu X; Zhan DD; Chen HH; Li HP; Liu LR; Chen X; Liu YH; Li Y; Bai JP; Ye S; Zhang HB
    Clin Lung Cancer; 2021 Jan; 22(1):e98-e111. PubMed ID: 33067127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.
    Wagener-Ryczek S; Heydt C; Süptitz J; Michels S; Falk M; Alidousty C; Fassunke J; Ihle MA; Tiemann M; Heukamp L; Wolf J; Büttner R; Merkelbach-Bruse S
    BMC Cancer; 2020 May; 20(1):408. PubMed ID: 32397977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
    Kita K; Fukuda K; Takahashi H; Tanimoto A; Nishiyama A; Arai S; Takeuchi S; Yamashita K; Ohtsubo K; Otani S; Yanagimura N; Suzuki C; Ikeda H; Tamura M; Matsumoto I; Yano S
    Cancer Sci; 2019 Oct; 110(10):3215-3224. PubMed ID: 31432603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.
    O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB
    Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts.
    Lavdovskaia ED; Iyevleva AG; Sokolenko AP; Mitiushkina NV; Preobrazhenskaya EV; Tiurin VI; Ivantsov AO; Bizin IV; Stelmakh LV; Moiseyenko FV; Karaseva NA; Orlov SV; Moiseyenko VM; Korzhenevskaya MA; Zaitsev IA; Kozak AR; Chistyakov IV; Akopov AL; Volkov NM; Togo AV; Imyanitov EN
    Oncol Res Treat; 2018; 41(10):634-642. PubMed ID: 30145586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
    van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
    Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2).
    Beau-Faller M; Texier M; Blons H; Richard N; Escande F; Melaabi S; Lizard S; De Fraipont F; Longchampt E; Morin F; Zalcman G; Pignon JP; Cadranel J
    Clin Lung Cancer; 2019 May; 20(3):222-230. PubMed ID: 30679079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR.
    Watanabe M; Kawaguchi T; Isa S; Ando M; Tamiya A; Kubo A; Saka H; Takeo S; Adachi H; Tagawa T; Kakegawa S; Yamashita M; Kataoka K; Ichinose Y; Takeuchi Y; Sakamoto K; Matsumura A; Koh Y
    Clin Cancer Res; 2015 Aug; 21(15):3552-60. PubMed ID: 25882755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
    Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
    Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic Assessment of Tissue and Plasma
    Ho HL; Wang FY; Chiang CL; Tsai CM; Chiu CH; Chou TY
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor].
    Cao ZY; Wu W; Hou LK; Zhang W; Gao CX; Wu CY; Zhang LP
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):910-914. PubMed ID: 30522170
    [No Abstract]   [Full Text] [Related]  

  • 40. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
    Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
    Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.